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developed HBV seroconversion. Overall, suwival in this small cohort was no different 
than that for all patients transplanted at our center during this time period. Conclusion: 
Transplantation of hearts from HBcAb+ donors is associated with a low HBV transmis- 
sion risk. Transplantation of hearts from donors with intracranial tumors is not associated 
with tumor transmission. Use of hearts from these marginal donors should be considered 
safe and may help to augment the available donor pool. 
1137-63 Recent Outcomes in Cardiac Transplant Patients 
Receiving Hepatitis C Allografts: A Single Center 
Experience 
Jaymica P. Patel, Jianesh K. Patel, Brandy T. Cole, Maria Espejo Vassilakis, Lynda 
Kessler, Bernard Kubak, Jon A. Kobashigawa. The David Geffen School of Medicine at 
UCLA, Los Angeles, CA 
Background: Hepatitis C infection in the non-immunocompromised population is a 
chronic progressive disease with clinical manifestations after several years, The long- 
term impact of hepatitis C following heart transplantation remains unclear. 
Methods: Medical records pertaining to heart transplant recipients receiving allografts 
from hepatitis C positive donors between August 1991 and August 2002 were reviewed 
retrospectively. 23 patients were identified as having received allografts from hepatitis C 
positive donors. Df these, 7 recipients were hepatitis C positive prior to transplantation 
and 9 patients were Status I listing. Overall survival was determined. The presence of 
diabetes mellitus, hypertension, renal function, post-transplant albumin, donor age, pra- 
transplant hepatitis C status and type of immunosuppression used were determined to 
assess possible contribution to outcomes. 
Results: Overall survival in patients receiving hepatitis C positive allografts was 57% at 
one year and 17% at 5 years. This compared to an overall one-year survival of 62% at 
one year and 70% at 5 years for all adult heart transplants. Cause of death was due to 
multisystem organ failure and/or sepsis (5) liver failure (2) transplant coronary disease 
(2) unexplained sudden death (2). malignancy (2) rejection (1) and pulmonary embolus 
(I). By multivariate analysis and logistic regression, the only significant predictor for mor- 
tality was low post-transplant albumin (p<O.O17). Pre-transplant hepatitis C status or type 
of immunosuppression used did not significantly affect outcome. 
Conclusion: Patients receiving hepatitis C positive cardiac aflografts have a significantly 
worse outcome when compared to the outcome for all adult heart transplants in our insti- 
tution. Their mortality compares to patients with severe heart failure. These data suggest 
that the use of cardiac allografts from hepatitis C positive donors should be restricted to 
critically ill patients awaiting transplantation for whom other treatment modalities are 
unsuitable. 
1137-64 The Vagrancy of B-Type Natriuretic Peptide Levels in 
Heart Transplant Recipients Receiving Tacrolimus 
Daniel Crua Maria Espejo Vassilakis, Jignesh K. P&l, Alan Garfinkel, Gregg Fonarow, 
Jaime Moriguchi, Jon A. Kobashigawa, The David Geffen School of Medicine at UCLA, 
Los Angeles, CA 
Background: Tacrolimus (FK506) is a potent immunosuppressant often used in place of 
cyclosporine (CSA) in heart transplant (HT) patients. Prior studies on HT patients on 
CSA have demonstrated that B-type natriuretic peptrde (BNP) levels are elevated and 
even continue to rise after HT. However, studies utilizing BNP as a marker of filling pres- 
sures and rejection have been discordant. It is unknown if the same BNP patterns exist 
for HT recipients receiving FK506. Methods: We retrospectively analyzed BNP levels I” 
49 patients on CSA or FK506 who were transplanted between August 2001 and May 
2002. 300 BNP levels were drawn at the time that hemodynamic measurements and 
ventricular biopsies were performed. Mean follow-up was 5.6 months. Recipients with 
end-stage renal disease and those followed by outside institutions were excluded. 
Results: Most patients receiving FK506 normalize BNP levels (slope -40.2, p<O.OOOl). 
26/33 patients (76%) reached BNP levels of <IO0 pg/ml by 4 months. Both the CSA and 
FK506 groups had similar ejectton fraction, pulmonary capillary wedge (PCW) pressure, 
and creatinine. In FK506 recipients, a weak correlation coefficient (r = 0.4) was observed 
between PCW and BNP. Utilizing a BNP level of 150 pglml and PCW of 14 mmHg, the 
sensitivity of the assay decreased from 100% during the first two months to 21% during 
the subsequent months. In contrast, the specificity of the assay increased from 34% to 
61% during the same time period. There were 7 episodes of rejection (3 cellular and 3 
humoral) in 6 HT recipients. Cases were not preceded by an increase in BNP in the days 
to weeks prior to presentation. Conclusions: Most patients on FK506 achieve normal 
BNP levels by 4 months in contrast to those reported HT patients on CSA. In HT patients 
on FK506, BNP appears to be an inadequate assay to screen for rejection or volume sta- 
tus. The mechanism by which FK506 suppresses BNP levels after OHT deserves further 
investigation. 
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J. Addonizio, Columbia University, New York, NY 
Background: Growth hormone (GH) is used to treat growth failure following cardiac trans- 
plantation (TX). GH can increase cardiac muscle mass and improve function in patients 
with cardiomyopathy. We evaluated the safety, efficacy and cardiac effects of GH in chil- 
dren following cardiac TX. 
Methods: Ten pediatric cardiac TX recipients with growth failure were followed serially for 
4 years before and after GH therapy. Parameters followed included growth velocity (GV), 
cyclosporine levels, frequency of rejection episodes, echocardiographic measures of car- 
diac function and dimensions, and hemodynamic measurements. To determine if out- 
comes were related to increased GV or to a direct effect of GH, these data were 
compared to measurements obtained in 6 age-matched pediatric cardiac TX recipients 
experiencing a natural growth spurt. Results: The mean age at TX in the GH group was 
7.6*1 yr with mean age at onset of GH therapy of 13*1 yr (mean duration, 2.5+1 yr). The 
mean GV increased following GH and was not different from controls (8.6*1 vs 7.1*1 
cmJyr). Cyclosporine levels were maintained during the growth spurt (312+34 vs 266+26 
ng/ml). The frequency of rejection episodes was not different in GH group compared to 
controls (0.1+0.2/yr vs 0.4*0.3/y& LV shortening fraction increased in GH group from 
36*2% to 44*2%, (~~0.05) and was higher compared to controls (37+2%. p<O.O5). The 
SF returned to baseline levels after discontinuation of GH. Cardiac index increased fol- 
lowing GH (3.2*0.3% to 3.9+0.2%, p=O.Ol) and was higher than controls (2.9*0.3%, 
pcO.01). Mixed venous saturations were higher following GH (76*1% to 7li2%, p<O.O5). 
The calculated LV mass increased from 95+11 g/m2 to 117+17 g/m2 following GH 
(p=O.Ol) and was higher than controls (95+7 g/m2, p<O.O5). LV mass/volume ratio was 
also higher in GH group (0.72+0.02) compared to controls (0.67iO.03, p=O.O5). Conclu- 
sion: GH IS a safe and effective therapy for growth failure in children following cardiac TX 
even in the absence of GH deficiency. GH therapy is also associated with short-term 
improvement in ventricular mass, cardiac function and hemodynamics. Whether these 
beneficial effects are sustained in the long term remains to be determined. 
1137-66 Survival Pre and Post-Heart Transplantation in Patients 
Listed as UNOS Status 2: Do UNOS Status 2 Patients 
Benefit From Transplantation? 
Javier Jimenez, Leah Bennett Edwards, Robert Higgins, Joseph Bauerlein, Si Pham, 
Stephen Mallon, Jackson Memorial Medical Center, Miami, FL, United Network for Organ 
Sharing, Richmond, VA 
Introduction: Improved outcomes with contemporary medical therapy in patients with 
advanced heart failure questions the benefit of transplantation (TX) in UNOS status 2 
patients. 
Methods: Between January 1999 and June 2001; 4,255 patients were listed for heart TX 
as UNOS status 2. Using a competing risk method, probabilities of events on the waiting 
list were computed. Additionally, a time dependent proportional hazards model was used 
to determine predictors of death pre and post TX. 
Results: Demographics of this cohort revealed a mean age of 52.3 years, female gender 
(23%) ischemic etiology (46%) diabetes (21%) white race (65%) and mean time on the 
waiting list (396.5 days). Relative risks of death (> 1 indicates an increased risk) com- 
pared to patients remaining on the waiting list as status 2 were: upgrade to status 1 A; RR 
14.9 (95%CI 9.7-22.2) upgrade to status 1 B; RR 3.4 (95%CI 2.4-4.7). O-7 days following 
TX as status 2; RR 16.7 (95%CI 9.3-30.2) and 7-33 days following TX as status 2; RR 
6.5 (95%CI 3.7-l 1.2). All factor were significant at p<O.OOOl. The overall relative risk of 
death following TX (365+ days) for status 2 patients initially listed as status 2 compared 
to those that continue to wait as status 2 is shown below; RR 0.92 (95%CI 0.5-I .56, 
p=O.6). 
Conclusion: After accounting for early perioperative mortality, there appears to be little 
suwival benefit at one year in transplantrng UNOS status 2 patients. The point of optimal 
benefit from TX in UNOS status 2 patients may need to be funther defined. 
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Luciano Potena. Francesco Grigioni, Fabio Coccolo. Gaia Magnani, Paolo Ortolanr, 
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Background. Graft coronary disease (GVD) is a major determinant of mortality after 
heart transplantation (HT). This peculiar form of atherosclerosis has been recently identi- 
fied as the result of the interaction between intimal hyperplasia and vessel wall response 
(i.e. vascular remodeling). Although immunological and traditional risk factors an? known 
to be implied in GVD pathogenesis, their contribution to remodeling process remains 
undetermined. 
Methods. 37 consecutive HT recipients were prospectively studied (age 52illyrs; 75% 
males; donor age 32il lyrs). lntracoronary ultrasound (IVUS) of proximal-mid left ante- 
rior descending was performed at 1 and 12 months after HT. Vessel, lumen and intimal 
volume changes over this period were analyzed. 
Results. 1169 IVUS images were obtained. Overall intimal volume increased (+60%. 
PcO.001) while vessel volume remained unchanged (P=O.2) and thus, lumen volume 
decreased (-9%, P=O.Ol). Among all the clinical and demographic characteristics ana- 
lyzed (e.g. donor features, immunosuppression, lipid panel, biopsy score), only the 
occurrence of cytomegalovirus (CMV) infection was associated with coronary lumen loss 
(P=O.O47). Patients who presented CMV infection (11~14) showed an higher increase in 
intimal volume (I 16% vs. 59%, P=O.O7), but not in vessel volume (+I% vs. +4%, P=O.5). 
Therefore, CMV infected patients showed a more significant lumen loss (-13% vs -3%, 
P=O.O4). A trend towards an association between LDL and intimal growth was present 
only in CMV infected recipients (R=0.46, P=O.O7). 
Conclusions. This prospective study suggests for the first time that occurrence of CMV 
infection during the first post-HT year negatively affects vascular remodeling, ultimately 
resulting in coronary lumen loss. LDL serum levels might contribute to lumen loss inter- 
acting with CMV infection in stimulating intimal growth. 
